Sugi Predict

Sugi Predict / Compounds / SCHEMBL806052

SCHEMBL806052

SCHEMBL806052

FC(F)(F)c1cccc(Nc2nccc3ccccc23)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 4/20 0.64
▸ EGFR P00533 4/20 0.64
▸ TSHR P16473 1/20 0.62
▸ HTT P42858 1/20 0.62
▸ AURKA O14965 2/20 0.56
▸ IDH2 P48735 1/20 0.55
▸ LMNA P02545 3/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ GMNN O75496 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ TTR P02766 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ UGT1A1 P22309 1/20 0.54
▸ PTGS1 P23219 1/20 0.54
▸ PTGS2 P35354 1/20 0.54
▸ PMP22 Q01453 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30398394 1.00 ABCG2 (0.64) ABCG2EGFRTSHRHTTAURKA
SCHEMBL29638686 0.84 EGFR (0.52) ABCG2EGFRTSHRHTTAURKA
SCHEMBL21611891 0.84 EPHX2 (0.54) ABCG2EGFRMEN1KMT2ATDP1
SCHEMBL30012626 0.84 EPHX2 (0.54) ABCG2EGFRMEN1KMT2ATDP1
SCHEMBL30754777 0.82 LMNA (0.65) ABCG2EGFRTSHRHTTAURKA
SCHEMBL15184200 0.81 EGFR (0.57) ABCG2EGFRTSHRHTTAURKA
SCHEMBL7127641 0.80 AHR (0.58) EGFRLMNAMEN1KMT2ATDP1
SCHEMBL1921849 0.78 ABCG2 (0.53) ABCG2EGFRTSHRAURKAMEN1
SCHEMBL4933191 0.78 TNF (0.64) ABCG2EGFRMEN1ALDH1A1CYP1A2
SCHEMBL26789989 0.78 TNF (0.64) ABCG2EGFRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3818046-B1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2023-05-10 — — EP claimed
US-20210275516-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF GLIAPHARM SA (CH) 2021-09-09 — — US claimed
EP-3818046-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2021-05-12 — — EP claimed
CN-112384503-A Lactic acid enhancing compounds and uses thereof 洛桑联邦理工学院(EPFL) 2021-02-19 — — CN claimed
WO-2020007807-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2020-01-09 — — WO claimed
WO-2013005168-A2 CANNABINOID RECEPTOR MODULATORS LUPIN LIMITED (IN) 2013-01-10 — — WO claimed
WO-2012090177-A2 CANNABINOID RECEPTOR MODULATORS LUPIN LIMITED (IN) 2012-07-05 — — WO claimed
EP-4065117-B1 ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME GLIAPHARM SA (CH) 2024-06-19 — — EP disclosed
US-11925632-B2 Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome GLIAPHARM SA (CH) 2024-03-12 — — US disclosed
EP-3818046-B1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2023-05-10 — — EP disclosed
US-20230102415-A1 ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME GLIAPHARM SA (CH) 2023-03-30 — — US disclosed
US-20210275516-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF GLIAPHARM SA (CH) 2021-09-09 — — US disclosed
EP-3845229-A1 ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME Gliapharm SA (CH) 2021-07-07 — — EP disclosed
EP-3818046-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2021-05-12 — — EP disclosed
CN-112384503-A Lactic acid enhancing compounds and uses thereof 洛桑联邦理工学院(EPFL) 2021-02-19 — — CN disclosed
WO-2020007807-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2020-01-09 — — WO disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 — — US disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 — — US disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 — — US disclosed
WO-2012037132-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS EXELIXIS, INC. (US) 2012-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11925632-B2 Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome SLC2A1, SLC2A2, SLC2A3 ABCG2 251/4885EGFR 4868/4885TSHR 3733/4885
US-20130165440-A1 JAK1 Inhibitors JAK1, JAK2, JAK3 ABCG2 2473/4885EGFR 712/4885TSHR 1965/4885
US-20210275516-A1 LACTATE ENHANCING COMPOUNDS AND USES THEREOF LDHA, LDHB, NLN ABCG2 3075/4885EGFR 4536/4885TSHR 4228/4885
US-20230102415-A1 ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME SLC2A1, SLC2A2, SLC2A3 ABCG2 251/4885EGFR 4868/4885TSHR 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.